News | October 03, 2013

Most U.S. Science Agencies Will Suffer From Government Shutdown

October 3, 2013 — Immediate U.S. government furloughs affecting virtually all National Science Foundation (NSF) employees and three-fourths of those at the National Institutes of Health (NIH) could impact U.S. competitiveness, American Association for the Advancement of Science (AAAS) warned.

"If the government shutdown continues for a week or more, it is going to make the United States less desirable as an international research collaborator," said Joanne Carney, director of the AAAS Office of Government Relations. "When funding is no longer reliable, many of our research partners may be unable to continue collaborating with us. That could eventually have longer-term impacts on American innovation and competitiveness."

Although some exceptions exist, the majority of staff and programs at national science agencies will be affected by the congressional stalemate that led to the current shutdown of the federal government.

Furloughs will impact the vast majority of staff at the NSF, for example, except for those directly responsible for the protection of life and property, which likely would include support for the agency's Antarctic research facilities and personnel.

"NSF will be sending notices to research grant awardees, informing them that payments won't be made during the disruption, although research that doesn't require federal employee intervention may proceed," said Matthew Hourihan, director, AAAS Research and Development Budget and Policy Program.

Within the U.S. Department of Health and Human Services, 40,512 employees, or 52 percent, of all staff are expected to be furloughed. At the National Institutes of Health (NIH) in particular, the furloughs will send 73 percent of employees home. Remaining NIH employees will continue to provide both inpatient and outpatient care, but the NIH Clinical Center will not be able to accept new patients.

The U.S. Food and Drug Administration (FDA) will be unable to support the majority of its food safety, nutrition, and cosmetics activities," according to an agency statement. The FDA will also have to cease safety activities such as routine establishment inspections, some compliance and enforcement activities, monitoring of imports, notification programs and the majority of the laboratory research necessary to inform public health decision-making.

The Centers for Disease Control and Prevention (CDC) furloughed all but one person to monitor all disease outbreaks in the Unifted States after the shutdown. However, about 30 CDC employees were  recalled to work this week following and outbreak of salmonella.  

Most of the 13,814 employees of the U.S. Department of Energy will be furloughed, leaving only a few hundred staff at the National Nuclear Security Administration. "Literally a handful of regular DOE staff would remain on the job within the Office of Science and programs for efficiency, renewables, nuclear power and fossil energy, including ARPA-E, but as contractor entities the labs will be shielded for a time," Hourihan said. The Advanced Research Projects Agency-Energy is responsible for identifying "out-of-the-box" energy solutions not supported by industry research.

The National Aeronautics and Space Administration’s (NASA) shutdown contingency plan ensures support for the International Space Station and its astronauts as well as other satellite missions now under way. NASA will not issue new contracts or grants, however, and most pre-launch development work will end.

Most staff at the National Institute of Food and Agriculture (NIFA) and the Economic Research Service also will be furloughed, Hourihan reported. The only exceptions will be a few hundred employees in charge of research animals and assets such as critical information technology.

Before fiscal year 2013 ended Sept. 30, the White House Office of Management and Budget established an online summary of the contingency plans for most agencies. With Congress unable to agree on how best to appropriate funds for the new fiscal year, most federal science programs and employees lost support as of midnight, Oct. 1. Exceptions included work at the Centers for Medicare and Medicaid Services, including much healthcare reform work in support of the Affordable Care Act, which had polarized budget negotiations on Capitol Hill.

"This doesn't mean all government-funded R&D will cease," Hourihan noted. "Extramural researchers who do not require immediate intervention or oversight from civil servants or are not waiting on disbursal of actual funding may continue their work."

The U.S. debt now stands at 73 percent of the U.S. gross domestic product (GDP), the Congressional Budget Office reported, and it could hit 100 percent by 2038. Federal Research and Development is considered "discretionary spending," and it has accounted for 11 to 12 percent of that category of expenses since the 1980s, Hourihan explained. Discretionary spending overall has been declining as a share of the overall federal budget though, and the CBO has said that discretionary spending will drop to 5.3 percent of the GDP by 2023.

Earlier this year, Hourihan reported that spending cuts mandated by the Budget Control Act, also known as sequestration, had reduced R&D spending for fiscal year 2013 to near 0.8 percent of the GDP — the lowest level seen in 40 years. Under a continuation of the budget sequester, he said, R&D as a share of GDP will likely drop below 0.8 percent for the first time in a long time.

"For years now, elected officials been targeting discretionary spending," Hourihan said. "They have not adequately addressed revenues. They have not adequately addressed entitlement spending. The forces that are driving federal spending and deficits have not been addressed. Once again, the U.S. government shutdown is an example of Congress attacking discretionary spending and the most valuable element of discretionary spending — research and development — without addressing the fundamental budget challenges."

For more information: www.aaas.org, www.hhs.gov, www.energy.gov, www.cbo.gov

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT)| September 15, 2017
Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init